HER3

SAN DIEGO--(BUSINESS WIRE)-- Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today announced the appointment of Enoch Kariuki, Pharm.D. as President and Vishaal Turakhia as Chief Financial Officer (CFO). Both Dr. Kariuki and Mr. Turakhia are established life sciences executives with extensive strategic, operational, and financial experience. This press release features multimedia. View the full release here: Enoch Kariuki, Pharm.D. (Photo: Business Wire) “We’re preparing for an important year ahead at Endeavor BioMedicines and I’m delighted that both Enoch and Vishaal are joining the company,” said John Hood, Ph.D., Co-founder, CEO and Chairman, Endeavor BioMedicines. "Enoch and Vishaal both have an outstanding track record of corporate development, operating and financial leadership that will be invaluable as we continue to advance the clinical development of ENV-101 and ENV-501 for fibrotic lung diseases and cancer.” Dr. Kariuki has more than 15 years of experience in healthcare strategy, life sciences investment banking, venture capital and business development. Most recently, he served as Chief Executive Officer of Lengo Therapeutics (acquired by Blueprint Medicines). Previously, Dr. Kariuki served as the Chief Financial Officer of VelosBio (acquired by Merck), where he led all finance-related and investor relations functions. Prior to VelosBio, he served as Senior Vice President, Corporate Development, at Synthorx, where he led the company’s IPO, managed relationships with bankers, sell-side equity analysts and investors, and headed the business development process that concluded with the sale of Synthorx to Sanofi. As a result of Dr. Kariuki’s new role as President, he will transition off of Endeavor BioMedicines’ Board of Directors. “I look forward to expanding my role with Endeavor as we continue to advance towards our clinical milestones,” said Dr. Kariuki. “I can see the distinct and very differentiated therapeutic benefits of the company’s two pipeline candidates and I’m thrilled to work alongside John and the rest of the management team.” Mr. Turakhia has 15 years of investment banking experience. Prior to joining Endeavor BioMedicines, Vishaal was a Managing Director in the Healthcare Investment Banking Group at Piper Sandler, where he advised management teams and boards of biopharma companies on a range of financing and strategic transactions. Prior to Piper Sandler, Vishaal was Vice President in the Healthcare Investment Banking Groups at Bank of America Merrill Lynch and RBC Capital Markets, and an Equity Research Analyst in the Healthcare Group at Goldman Sachs, where he covered SMID-cap biopharma companies. During his career, Vishaal has executed more than 80 transactions, including over $50 billion in equity and debt financings and M&A. “I am honored to join Endeavor BioMedicines' highly credentialed leadership team as we continue building a strong financial foundation to advance our programs and create significant value for all key stakeholders,” said Mr. Turakhia. “I am particularly excited to be a part of this team's vision to develop groundbreaking medicines that have the potential to reverse the trajectory of relentless diseases." About Endeavor BioMedicines Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases. Endeavor’s lead candidate, ENV-101, is an inhibitor of the Hedgehog (Hh) signaling pathway in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive fibrosing-interstitial lung disease (PF-ILD). Their second candidate, ENV-501, is a HER3-antibody drug conjugate (ADC) for the treatment of HER3-positive solid tumors. More information is available at and on LinkedIn or X.

SINGAPORE and HANOVER, Germany, March 13, 2024 /PRNewswire/ -- Hummingbird Bioscience and Dartmouth's Geisel School of Medicine today announced that the 3rd Annual VISTA Symposium will take place virtually on Wednesday, March 27, 2024 (11:00 AM - 3:30 PM ET). VISTA is a novel immune checkpoint implicated in various cancers. There is broad potential clinical impact for cancer patients, with strong scientific evidence that VISTA-mediated immune suppression plays a key role in many solid tumors, including triple-negative breast cancer, non-small cell lung cancer and head and neck squamous cell carcinoma. High VISTA expression in tumor correlates with poor survival in cancer patients and has been associated with a lack of response to other immune checkpoint inhibitors. Pre-clinical data on VISTA biology and VISTA targeting have shown potent anti-tumor effects, and clinical readouts are expected this year. The symposium will explore the important role of VISTA in cancer immunotherapy. Along with updates on the ongoing clinical development of anti-VISTA therapies, renowned scientific experts, clinicians, and industry leaders will share the latest insights on VISTA biology, and the growing potential of VISTA as a therapeutic target in multiple cancer indications. Register here. Symposium Information Title: 3rd Annual VISTA Symposium: VISTA – Clinical updates and biological insights on a promising new target in cancer immunotherapy Date: Wednesday, March 27, 2024 Time: 11:00 AM - 3:30 PM ET Following a keynote presentation by John Connolly, PhD (Chief Scientific Officer, Parker Institute for Cancer Immunotherapy), the day will include short presentations, panel discussions and Q&A sessions by VISTA experts that will contextualize the exciting data and highlight why VISTA is the immunotherapy target to watch in 2024. Agenda Opening Remarks (11:00 AM - 11:10 AM ET) Piers Ingram, PhD – Chief Executive Officer and Co-Founder, Hummingbird Bioscience Keynote (11:10 AM - 11:30 AM ET) John Connolly, PhD – Chief Scientific Officer, Parker Institute for Cancer Immunotherapy VISTA Biology (11:30 AM - 12:30 PM ET) Randolph Noelle, PhD – Emeritus Professor of Microbiology and Immunology, Geisel School of Medicine J. Louise Lines, PhD – Research Scientist, Geisel School of Medicine Li Lily Wang, PhD – Associate Staff, Lerner Research Institute, Cleveland Clinic Sietse J. Luk, MD – Research Scientist, Department of Hematology, Leiden University Medical Center VISTA Targeting and Potential Biomarkers (12:30 PM - 1:15 PM ET) Bhushan Dharmadhikari, PhD – Principal Scientist, Hummingbird Bioscience Sven Mostböck, PhD – Principal Scientist, Boehringer Ingelheim Robert Martell, MD, PhD – Chief Scientific Officer, Curis VISTA and Clinical Opportunities (1:30 PM - 2:30 PM ET) Joshua Gruber, MD, PhD – Assistant Professor, Department of Internal Medicine, University of Texas, Southwestern Medical Center P. Jack Hoopes, DVM, PhD – Professor of Surgery, Professor of Medicine, Geisel School of Medicine Jing Fu, PhD – Research Scientist, Vagelos College of Physicians and Surgeons, Columbia University Matthew Vesely, MD, PhD – Assistant Professor of Dermatology, Yale School of Medicine Anti-VISTA Immunotherapies in Clinical Development (2:30 PM – 3:30 PM ET) Edward van der Horst, PhD – Chief Scientific Officer, Sensei Bio Jerome Boyd-Kirkup, PhD – Chief Scientific Officer and Co-Founder, Hummingbird Bioscience Thierry Guillaudeux, PhD – Chief Scientific Officer, Kineta Follow this link for updates. About Hummingbird Bioscience Hummingbird Bioscience is a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases. The Hummingbird Bioscience model combines computational and systems biology with wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. The company harnesses this integrated approach across target identification and patient selection, enabling the team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. The company is currently developing two clinical-stage assets: HMBD-001, a humanized anti-HER3 monoclonal antibody targeting a novel epitope on HER3, and HMBD-002, a humanized anti-VISTA IgG4 monoclonal antibody. Both programs are currently in Phase I studies. At Hummingbird Bioscience, the commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. For more information, please visit , and follow Hummingbird Bioscience on LinkedIn, X (formerly Twitter), and YouTube. About Geisel School of Medicine Founded in 1797, the Geisel School of Medicine at Dartmouth strives to improve the lives of the communities it serves through excellence in learning, discovery, and healing. The Geisel School of Medicine is renowned for its leadership in medical education, healthcare policy and delivery science, biomedical research, global health, and in creating innovations that improve lives worldwide. As one of America's leading medical schools, Dartmouth's Geisel School of Medicine is committed to training new generations of diverse leaders who will help solve our most vexing challenges in healthcare. Hummingbird Bioscience Contacts: Crystal Ho [email protected] [email protected] +65 6979 5580 [email protected] Geisel School of Medicine Contacts: Derik Hertel Director of Communications & Marketing Phone: (603) 646-5100 Email: [email protected] [email protected]

SINGAPORE and HANOVER, Germany, March 13, 2024 /PRNewswire/ -- Hummingbird Bioscience and Dartmouth's Geisel School of Medicine today announced that the 3rd Annual VISTA Symposium will take place virtually on Wednesday, March 27, 2024 (11:00 AM - 3:30 PM ET). VISTA is a novel immune checkpoint implicated in various cancers. There is broad potential clinical impact for cancer patients, with strong scientific evidence that VISTA-mediated immune suppression plays a key role in many solid tumors, including triple-negative breast cancer, non-small cell lung cancer and head and neck squamous cell carcinoma. High VISTA expression in tumor correlates with poor survival in cancer patients and has been associated with a lack of response to other immune checkpoint inhibitors. Pre-clinical data on VISTA biology and VISTA targeting have shown potent anti-tumor effects, and clinical readouts are expected this year. The symposium will explore the important role of VISTA in cancer immunotherapy. Along with updates on the ongoing clinical development of anti-VISTA therapies, renowned scientific experts, clinicians, and industry leaders will share the latest insights on VISTA biology, and the growing potential of VISTA as a therapeutic target in multiple cancer indications. Register here. Symposium Information Title: 3rd Annual VISTA Symposium: VISTA – Clinical updates and biological insights on a promising new target in cancer immunotherapy Date: Wednesday, March 27, 2024 Time: 11:00 AM - 3:30 PM ET Following a keynote presentation by John Connolly, PhD (Chief Scientific Officer, Parker Institute for Cancer Immunotherapy), the day will include short presentations, panel discussions and Q&A sessions by VISTA experts that will contextualize the exciting data and highlight why VISTA is the immunotherapy target to watch in 2024. Agenda Opening Remarks (11:00 AM - 11:10 AM ET) Piers Ingram, PhD – Chief Executive Officer and Co-Founder, Hummingbird Bioscience Keynote (11:10 AM - 11:30 AM ET) John Connolly, PhD – Chief Scientific Officer, Parker Institute for Cancer Immunotherapy VISTA Biology (11:30 AM - 12:30 PM ET) Randolph Noelle, PhD – Emeritus Professor of Microbiology and Immunology, Geisel School of Medicine J. Louise Lines, PhD – Research Scientist, Geisel School of Medicine Li Lily Wang, PhD – Associate Staff, Lerner Research Institute, Cleveland Clinic Sietse J. Luk, MD – Research Scientist, Department of Hematology, Leiden University Medical Center VISTA Targeting and Potential Biomarkers (12:30 PM - 1:15 PM ET) Bhushan Dharmadhikari, PhD – Principal Scientist, Hummingbird Bioscience Sven Mostböck, PhD – Principal Scientist, Boehringer Ingelheim Robert Martell, MD, PhD – Chief Scientific Officer, Curis VISTA and Clinical Opportunities (1:30 PM - 2:30 PM ET) Joshua Gruber, MD, PhD – Assistant Professor, Department of Internal Medicine, University of Texas, Southwestern Medical Center P. Jack Hoopes, DVM, PhD – Professor of Surgery, Professor of Medicine, Geisel School of Medicine Jing Fu, PhD – Research Scientist, Vagelos College of Physicians and Surgeons, Columbia University Matthew Vesely, MD, PhD – Assistant Professor of Dermatology, Yale School of Medicine Anti-VISTA Immunotherapies in Clinical Development (2:30 PM – 3:30 PM ET) Edward van der Horst, PhD – Chief Scientific Officer, Sensei Bio Jerome Boyd-Kirkup, PhD – Chief Scientific Officer and Co-Founder, Hummingbird Bioscience Thierry Guillaudeux, PhD – Chief Scientific Officer, Kineta Follow this link for updates. About Hummingbird Bioscience Hummingbird Bioscience is a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases. The Hummingbird Bioscience model combines computational and systems biology with wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. The company harnesses this integrated approach across target identification and patient selection, enabling the team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. The company is currently developing two clinical-stage assets: HMBD-001, a humanized anti-HER3 monoclonal antibody targeting a novel epitope on HER3, and HMBD-002, a humanized anti-VISTA IgG4 monoclonal antibody. Both programs are currently in Phase I studies. At Hummingbird Bioscience, the commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. For more information, please visit , and follow Hummingbird Bioscience on LinkedIn, X (formerly Twitter), and YouTube. About Geisel School of Medicine Founded in 1797, the Geisel School of Medicine at Dartmouth strives to improve the lives of the communities it serves through excellence in learning, discovery, and healing. The Geisel School of Medicine is renowned for its leadership in medical education, healthcare policy and delivery science, biomedical research, global health, and in creating innovations that improve lives worldwide. As one of America's leading medical schools, Dartmouth's Geisel School of Medicine is committed to training new generations of diverse leaders who will help solve our most vexing challenges in healthcare. Hummingbird Bioscience Contacts: Crystal Ho [email protected] [email protected] +65 6979 5580 [email protected] Geisel School of Medicine Contacts: Derik Hertel Director of Communications & Marketing Phone: (603) 646-5100 Email: [email protected] [email protected] SOURCE Hummingbird Bioscience